QQQ   444.82 (+0.00%)
AAPL   171.95 (-0.78%)
MSFT   420.96 (-0.11%)
META   488.82 (-1.02%)
GOOGL   151.19 (+0.21%)
AMZN   180.50 (+0.37%)
TSLA   176.03 (-2.11%)
NVDA   905.28 (+0.31%)
NIO   4.51 (-3.43%)
AMD   180.38 (+0.44%)
BABA   72.43 (+1.17%)
T   17.64 (+0.51%)
F   13.24 (+1.38%)
MU   117.94 (-1.01%)
CGC   8.41 (-11.94%)
GE   175.39 (-2.63%)
DIS   122.28 (+1.07%)
AMC   3.65 (-15.90%)
PFE   27.84 (+0.22%)
PYPL   67.26 (+1.04%)
XOM   116.07 (+0.96%)
QQQ   444.82 (+0.00%)
AAPL   171.95 (-0.78%)
MSFT   420.96 (-0.11%)
META   488.82 (-1.02%)
GOOGL   151.19 (+0.21%)
AMZN   180.50 (+0.37%)
TSLA   176.03 (-2.11%)
NVDA   905.28 (+0.31%)
NIO   4.51 (-3.43%)
AMD   180.38 (+0.44%)
BABA   72.43 (+1.17%)
T   17.64 (+0.51%)
F   13.24 (+1.38%)
MU   117.94 (-1.01%)
CGC   8.41 (-11.94%)
GE   175.39 (-2.63%)
DIS   122.28 (+1.07%)
AMC   3.65 (-15.90%)
PFE   27.84 (+0.22%)
PYPL   67.26 (+1.04%)
XOM   116.07 (+0.96%)
QQQ   444.82 (+0.00%)
AAPL   171.95 (-0.78%)
MSFT   420.96 (-0.11%)
META   488.82 (-1.02%)
GOOGL   151.19 (+0.21%)
AMZN   180.50 (+0.37%)
TSLA   176.03 (-2.11%)
NVDA   905.28 (+0.31%)
NIO   4.51 (-3.43%)
AMD   180.38 (+0.44%)
BABA   72.43 (+1.17%)
T   17.64 (+0.51%)
F   13.24 (+1.38%)
MU   117.94 (-1.01%)
CGC   8.41 (-11.94%)
GE   175.39 (-2.63%)
DIS   122.28 (+1.07%)
AMC   3.65 (-15.90%)
PFE   27.84 (+0.22%)
PYPL   67.26 (+1.04%)
XOM   116.07 (+0.96%)
QQQ   444.82 (+0.00%)
AAPL   171.95 (-0.78%)
MSFT   420.96 (-0.11%)
META   488.82 (-1.02%)
GOOGL   151.19 (+0.21%)
AMZN   180.50 (+0.37%)
TSLA   176.03 (-2.11%)
NVDA   905.28 (+0.31%)
NIO   4.51 (-3.43%)
AMD   180.38 (+0.44%)
BABA   72.43 (+1.17%)
T   17.64 (+0.51%)
F   13.24 (+1.38%)
MU   117.94 (-1.01%)
CGC   8.41 (-11.94%)
GE   175.39 (-2.63%)
DIS   122.28 (+1.07%)
AMC   3.65 (-15.90%)
PFE   27.84 (+0.22%)
PYPL   67.26 (+1.04%)
XOM   116.07 (+0.96%)
NASDAQ:FATE

Fate Therapeutics (FATE) Stock Price, News & Analysis

$7.44
+0.10 (+1.36%)
(As of 03:10 PM ET)
Today's Range
$7.23
$7.65
50-Day Range
$4.33
$8.35
52-Week Range
$1.63
$8.83
Volume
1.15 million shs
Average Volume
2.92 million shs
Market Capitalization
$738.35 million
P/E Ratio
N/A
Dividend Yield
N/A
Price Target
$6.80

Fate Therapeutics MarketRank™ Stock Analysis

Analyst Rating
Hold
2.20 Rating Score
Upside/​Downside
8.8% Downside
$6.80 Price Target
Short Interest
Bearish
15.17% of Float Sold Short
Dividend Strength
N/A
Sustainability
-0.70
Upright™ Environmental Score
News Sentiment
0.78mentions of Fate Therapeutics in the last 14 days
Based on 12 Articles This Week
Insider Trading
Selling Shares
$199,732 Sold Last Quarter
Proj. Earnings Growth
Growing
From ($1.89) to ($1.76) Per Share

Overall MarketRank

New Rank-Based ScoringMarketRank is calculated by averaging available category scores (with extra weight given to analysis and valuation), then ranking the company's weighted average against that of other companies.

3.61 out of 5 stars

Medical Sector

310th out of 938 stocks

Biological Products, Except Diagnostic Industry

44th out of 154 stocks

FATE stock logo

About Fate Therapeutics Stock (NASDAQ:FATE)

Fate Therapeutics, Inc., a clinical-stage biopharmaceutical company, develops programmed cellular immunotherapies for cancer and immune disorders worldwide. The company's chimeric antigen receptor (CAR)-targeted NK and T-cell product candidates include FT576 to treat multiple myeloma, and FT522, to treat lymphoma and autoimmune disorders. Its CAR T-cell programs include FT819 to treat hematologic malignancies and solid tumors, and FT825 to treat solid tumors. The company has a collaboration and option agreement with Ono Pharmaceutical Co. Ltd. for the development and commercialization of off-the-shelf, iPSC-derived CAR T-cell product candidates for the treatment of cancer. Fate Therapeutics, Inc. was incorporated in 2007 and is headquartered in San Diego, California.

FATE Stock Price History

FATE Stock News Headlines

AI to Meet the Same Fate as EVs?
When these tech bubbles burst, they invariably leave investors disillusioned by their losses. Now, many worry a similar fate is awaiting AI. And one man, legendary financial analyst Porter Stansberry, who called Nvidia at $11…
Fate Therapeutics (NASDAQ:FATE) Trading Down 7%
Evaluating Fate Therapeutics: Insights From 5 Financial Analysts
AI to Meet the Same Fate as EVs?
When these tech bubbles burst, they invariably leave investors disillusioned by their losses. Now, many worry a similar fate is awaiting AI. And one man, legendary financial analyst Porter Stansberry, who called Nvidia at $11…
FATE Apr 2024 5.000 put
FATE Aug 2024 5.000 put
FATE Apr 2024 7.500 put
FATE Mar 2024 10.000 put
TD Cowen Keeps Their Buy Rating on Merus (MRUS)
Q4 2023 Fate Therapeutics Inc Earnings Call
See More Headlines
Receive FATE Stock News and Ratings via Email

Sign-up to receive the latest news and ratings for Fate Therapeutics and its competitors with MarketBeat's FREE daily newsletter.

Company Calendar

Last Earnings
2/26/2024
Today
3/28/2024
Next Earnings (Estimated)
5/01/2024
Fiscal Year End
12/31/2024

Industry, Sector and Symbol

Sector
Medical
Industry
Biological products, except diagnostic
Sub-Industry
N/A
Current Symbol
NASDAQ:FATE
Fax
N/A
Employees
181
Year Founded
N/A

Price Target and Rating

Average Stock Price Target
$6.80
High Stock Price Target
$10.00
Low Stock Price Target
$5.00
Potential Upside/Downside
-8.8%
Consensus Rating
Hold
Rating Score (0-4)
2.20
Research Coverage
10 Analysts

Profitability

Net Income
$-160,930,000.00
Net Margins
-253.30%
Pretax Margin
-253.30%

Debt

Sales & Book Value

Annual Sales
$63.53 million
Book Value
$3.74 per share

Miscellaneous

Free Float
94,236,000
Market Cap
$740.33 million
Optionable
Optionable
Beta
1.67
7 AI Stocks to Invest In: An Introduction to AI Investing For Self-Directed Investors Cover

As the AI market heats up, investors who have a vision for artificial intelligence have the potential to see real returns. Learn about the industry as a whole as well as seven companies that are getting work done with the power of AI.

Get This Free Report

FATE Stock Analysis - Frequently Asked Questions

Should I buy or sell Fate Therapeutics stock right now?

10 Wall Street equities research analysts have issued "buy," "hold," and "sell" ratings for Fate Therapeutics in the last year. There are currently 8 hold ratings and 2 buy ratings for the stock. The consensus among Wall Street equities research analysts is that investors should "hold" FATE shares. A hold rating indicates that analysts believe investors should maintain any existing positions they have in FATE, but not buy additional shares or sell existing shares.
View FATE analyst ratings
or view top-rated stocks.

What is Fate Therapeutics' stock price target for 2024?

10 analysts have issued twelve-month price objectives for Fate Therapeutics' stock. Their FATE share price targets range from $5.00 to $10.00. On average, they anticipate the company's stock price to reach $6.80 in the next year. This suggests that the stock has a possible downside of 8.8%.
View analysts price targets for FATE
or view top-rated stocks among Wall Street analysts.

How have FATE shares performed in 2024?

Fate Therapeutics' stock was trading at $3.74 at the beginning of 2024. Since then, FATE stock has increased by 99.5% and is now trading at $7.46.
View the best growth stocks for 2024 here
.

When is Fate Therapeutics' next earnings date?

The company is scheduled to release its next quarterly earnings announcement on Wednesday, May 1st 2024.
View our FATE earnings forecast
.

How were Fate Therapeutics' earnings last quarter?

Fate Therapeutics, Inc. (NASDAQ:FATE) announced its quarterly earnings results on Monday, February, 26th. The biopharmaceutical company reported ($0.45) earnings per share (EPS) for the quarter, beating analysts' consensus estimates of ($0.57) by $0.12. The biopharmaceutical company had revenue of $1.68 million for the quarter, compared to the consensus estimate of $0.85 million. Fate Therapeutics had a negative net margin of 253.30% and a negative trailing twelve-month return on equity of 38.17%. During the same period last year, the company posted ($0.58) EPS.

What ETF holds Fate Therapeutics' stock?

iShares Genomics Immunology and Healthcare ETF holds 348,530 shares of FATE stock, representing 0.86% of its portfolio.

What is Scott Wolchko's approval rating as Fate Therapeutics' CEO?

2 employees have rated Fate Therapeutics Chief Executive Officer Scott Wolchko on Glassdoor.com. Scott Wolchko has an approval rating of 100% among the company's employees. This puts Scott Wolchko in the top 10% of approval ratings compared to other CEOs of publicly-traded companies.

What other stocks do shareholders of Fate Therapeutics own?
Who are Fate Therapeutics' major shareholders?

Fate Therapeutics' stock is owned by a variety of retail and institutional investors. Top institutional shareholders include Vanguard Group Inc. (9.43%), Vanguard Group Inc. (9.36%), Point72 Asset Management L.P. (3.54%), Monaco Asset Management SAM (2.21%), Federated Hermes Inc. (1.88%) and Vestal Point Capital LP (1.31%). Insiders that own company stock include Bahram Valamehr, Brian T Powl, Cindy Tahl, Edward J Dulac III, J Scott Wolchko, John Mendlein, Louis T Petrillo, Mark Plavsic, Redmile Group, Llc, Shefali Agarwal, Yuan Xu and Yu-Waye Chu.
View institutional ownership trends
.

How do I buy shares of Fate Therapeutics?

Shares of FATE stock can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include Charles Schwab, E*TRADE, Fidelity, and Vanguard Brokerage Services.
Compare Top Brokerages Here.

This page (NASDAQ:FATE) was last updated on 3/28/2024 by MarketBeat.com Staff

From Our Partners